Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 187 participants.

Also called NCT03904693

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 187 participants (enrolled count) (from the registry)
Sponsor
  • Actelion Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03904693
  • EudraCT 2014-004786-25
Other papers using this trial's data
  • Long-Term Treatment with Single-Tablet Combination of Macitentan and Tadalafil in Pulmonary Arterial Hypertension: Results from A DUE and Its Open-Label Period Advances in therapy, 2026-05 DOI, PubMed 41820779, PMC13156223 In the PMC Open Access subset under CC BY-NC.
  • Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension Journal of the American College of Cardiology, 2024-01-30 DOI, PubMed 38267108

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Brazil, Bulgaria, Canada, China, Czechia, Germany, Hungary, Italy, Japan, Malaysia, Mexico, Poland, Russia, South Africa, Spain, Taiwan, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03904693. Randomized; quadruple masking; primary purpose treatment. Start 2019-07-29 (actual); primary completion 2022-08-23 (actual). Results posted on 2023-11-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Acronym
A DUE
Condition
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Intervention (Drug)
FDC macitentan/tadalafil
Intervention (Drug)
Macitentan 10 mg
Intervention (Drug)
Tadalafil 40 mg
Intervention (Drug)
Placebo FDC
Intervention (Drug)
Placebo macitentan
Intervention (Drug)
Placebo tadalafil
Lead sponsor
Actelion (class: industry)

Record details

Record id
cardio:ct-nct03904693
Content hash
118067d9e20cceb96c3993725e1dfac08bdb55292844f3d01ac572d5c580a423